Loading page
Loading page
Loading substance route
Insufflation is strongly discouraged due to significantly increased risk of fatal overdose. The potency of this substance and narrow margin between active and toxic doses make accurate dosing in the microgram range extremely difficult via this route. If handled as pure powder, laboratory safety methods (goggles, gloves, mask) must be used to prevent accidental exposure through inhalation or contact with mucous membranes.
Effects vary widely by individual, dose, and context.
The physical effects of 25C-NBOMe can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of 25C-NBOMe are described by many as remarkably light and underwhelming in comparison to more traditional psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages, however, mild to overwhelming cognitive alterations become present; this dosage seems to be lower in proportion to physical effects when compared to 25I-NBOMe.
25C-NBOMe presents a full and complete array of possible visual enhancements.
The visual geometry that is present throughout this trip is often described as very similar in appearance to that of LSD. They can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colourful in scheme, glossy in colour, sharp around the edges and mostly rounded across their corners. In comparison to other more commonly used psychedelics, they can be described as significantly more intricate than the visual geometry found within 2C-I and most of the 2C-x family in general as well as completely on par with LSD, Psilocin and DMT at appropriately high dosages, which seem lower in proportion to the accompanying physical effects when compared to that of 25I-NBOMe. In terms of their behaviour, 25C-NBOMe's geometry leads onto Level 8A visual geometry with Level 8B remaining so far unconfirmed within this substance. They also seem to consistently build up in visual intensity when the tripper stares at a central point. This eventually envelopes the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.
25C-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 - 5 hallucinatory breakthroughs are reported but very uncommon and inconsistent in comparison to other more commonly used psychedelics such as psilocin, 2C-E and DMT. This can be considered as on par with and identical in behaviour to that of LSD and 25I-NBOMe.
The auditory effects of 25C-NBOMe are common in their occurrence and exhibit a full range of effects.
25C-NBOMe is not habit-forming and the desire to use it can actually decrease with use. Due to its immediate tolerance buildup, compulsive use is essentially impossible. It is most often self-regulating.
The LD50 has not been determined. 25C-NBOMe can be fatal at heavy doses, with fatalities reported at doses as low as 4mg. Dangerous side effects begin to appear when exceeding 1000μg, with potentially lethal effects for sensitive individuals at approximately 2000μg. Overdose may occur at as little as double an average dose. The margin between a normal dose and overdose is extremely small compared to many other substances. Multiple deaths have occurred due to the ease of accidental overdose, particularly via insufflation.
Overdose can produce dangerously elevated heart rate and blood pressure, significant vasoconstriction, and in extreme cases cardiac arrest; peripheral vasoconstriction severe enough to require medical attention has been reported even at non-overdose levels.
Rhabdomyolysis has been documented in association with 25C-NBOMe use, representing serious risk of muscle tissue breakdown.
Anxiety and paranoia occur more readily with 25C-NBOMe than with other psychedelics, possibly due to its prominent stimulating properties. Overdose effects include confusion, delirium, delusions, panic attacks, and aggressive behavior.
Seizures are a documented risk with NBOMe compounds and appear more frequently during overdose situations. Muscle spasms, dystonia, and clonus have also been reported.
25C-NBOMe was discovered in 2003 by Ralf Heim at the Free University of Berlin. The compound was subsequently investigated by a research team at Purdue University led by David Nichols, and was first formally described in the scientific literature by Anders Ettrup and colleagues in 2010.…
Prohibited since June 26, 2019 under the Suchtmittelgesetz (SMG). Possession, production, and sale are illegal.
Controlled as of October 31, 2016 as a derivative of 2,5-dimethoxyphenethylamine under the Controlled Drugs and Substances Act.
Prohibited under national controlled substances legislation.
The NBOMe series became controlled in May 2013.
Designated as a narcotic drug effective November 1, 2015.
Considered substantially similar in chemical structure to the controlled hallucinogen DOB and therefore treated as a Class C controlled drug analogue. Withdrawn from sale in early 2012 following a statement by Associate Health Minister Peter Dunne.
Added to Schedule I (substances without medical use) as of August 1, 2013, published in Medical Products Agency regulation LVFS 2013:15.
Classified as a controlled drug. Possession, production, supply, and import are prohibited.
Emergency scheduled by the DEA on November 15, 2013, along with 25B-NBOMe and 25I-NBOMe under the Controlled Substances Act. The temporary scheduling was extended in November 2015. Several states including Arkansas, Georgia, and Louisiana added it to their Schedule I lists prior to federal action. Scheduling also makes other NBOMe compounds probable Controlled Substance Analogues when intended for human consumption.
Listed on Portaria SVS/MS nº 344 as of February 18, 2014. The entire NBOMe series became controlled at this time, including 25I-, 25C-, 25D-, 25B-, 25E-, 25N-, 25P-, 25T2-, 25T7-, and 25H-NBOMe.
Classified as a controlled substance since October 2015.
Listed in Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license are prohibited.
Classified as a Schedule I controlled substance. Possession, distribution, and manufacture are illegal.
Classified as a Schedule I controlled substance.
The entire NBOMe series became controlled in October 2011, making Russia the first country to regulate this class of substances.
Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation.
Controlled as a Class A substance since June 2014 under the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971. Previously subject to a temporary class drug order from June 10, 2013.
